Nu Skin (NUS) Q4 2025 earnings review
Shrinking Core Overshadows 'Intelligent Wellness' Pivot
Nu Skin's transformation is proving painful. Q4 revenue fell nearly 17% to $370M, with declines across every single geography and segment. Even excluding the sale of Mavely, organic revenue dropped over 10%. Crucially, the sales leader count—the engine of any direct selling model—collapsed by 19%. Management projects a return to growth by the end of 2026 driven by the 'Prysm iO' launch and India expansion, but guidance for Q1 2026 implies a continued steep decline (-12% at midpoint).
🐂 Bull Case
Despite top-line deterioration, disciplined cost control allowed Nu Skin to deliver $0.29 EPS (GAAP) and positive operating margins (6.3%). The balance sheet remains solid with a net cash position.
The company is betting on the 'Prysm iO' device (20,000 units already in leaders' hands) and entry into India (market opening H2 2026) to reverse trends. Early adoption metrics for the device are the primary monitorable for a turnaround.
🐻 Bear Case
Sales Leaders dropped 19% YoY to just ~30,000. In a direct selling model, revenue lags leader count; this steep decline suggests the bottom in revenue has not yet been reached.
Rhyz Manufacturing, previously a growth highlight (+17% in Q2), reversed course to shrink 11.3% in Q4. Losing this diversification lever exposes the company fully to the struggling direct-selling core.
⚖️ Verdict: 🔴
Bearish. The 19% loss in Sales Leaders is a structural red flag that outweighs promises of future product launches. Until the sales force stabilizes, the revenue floor remains unknown.
Key Themes
Core Engine Failure: Sales Leaders Decline
The health of a Multi-Level Marketing (MLM) entity relies on 'Sales Leaders.' This metric has deteriorated acceleratingly throughout 2025, ending Q4 down 19% YoY. Customers (-10%) and Paid Affiliates (-11%) also fell. Without a reversal in leader retention, the 'return to growth' projected for late 2026 is mathematically improbable.
Universal Geographic Weakness
There were no regional safe havens in Q4. Every reported region posted negative growth. Southeast Asia/Pacific, often a growth engine for direct sellers, slumped nearly 23%. Mainland China, a critical margin contributor, remains in secular decline (-7.8%).
Rhyz Manufacturing Reversal
Reversing. Earlier in FY25 (Q2), Rhyz Manufacturing was a bright spot growing 17%. In Q4, this segment turned into a drag, falling 11.3% YoY to $42.5M. This indicates that third-party manufacturing demand—or Nu Skin's internal demand flow-through—has softened significantly.
Prysm iO Deployment
Management's primary bull thesis rests on 'Prysm iO,' an intelligent wellness device. 20,000 devices are currently with sales leaders, generating 700,000 scans. The strategy is to convert these scans into personalized supplement subscriptions (recurring revenue). The success of this pivot is the sole bridge to the projected late-2026 recovery.
Mavely Sale Distortion
The sale of Mavely (social commerce platform) distorts YoY comparisons. While it generated a gain improving GAAP EPS, it creates a revenue headwind. 'Rhyz Other' revenue collapsed 82.8% in Q4 as expected. Investors must focus on the 'Excluding Mavely' numbers (-10.4% revenue decline) to gauge organic health.
Other KPIs
Down 19% YoY. This is the lowest level in recent history and represents a significant erosion of the company's distribution capability.
Stable/Improving. While headline numbers look volatile due to prior year inventory write-offs, the underlying Nu Skin business margin improved to 77.6% (vs 67.5% in 24Q4). This confirms pricing power or cost reductions on goods sold remains intact despite volume drops.
Stable. Up from $186.9M a year ago. The company maintains a net cash position, ensuring solvency during this transition period despite the earnings pressure.
Guidance
Decelerating. The midpoint ($330M) implies an 11% sequential drop from Q4 levels and a 12% to 7% YoY decline. This contradicts the 'stabilization' narrative in the short term.
Negative to Stable. The range implies growth between -9% and +1%. Given the weak Q1 guide, this forecast is heavily back-loaded, relying on a massive H2 recovery driven by India and new products.
Resetting lower. Compared to FY25 GAAP EPS of $3.18 (inflated by Mavely gain), this is a sharp optical drop. Compared to FY25 Adjusted EPS (approx $1.27), it indicates flat-to-down earnings power for the coming year.
Key Questions
Reversing Leader Churn
Sales Leaders are down 19% YoY. Specifically, what incentive changes or 'Prysm iO' attachment rates are you seeing in Q1 that give confidence this metric will floor in 2026?
Rhyz Manufacturing Weakness
Rhyz Manufacturing swung from +17% growth in Q2 to -11% contraction in Q4. Is this driven by internal volume declines or a loss of external third-party customers?
India Cash Burn vs. Contribution
With the India launch scheduled for H2 2026, what is the expected drag on operating margins in H1 due to pre-opening costs, and when do you expect the region to be profit-accretive?